Eledon Pharmaceuticals, Inc.
ELDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001404281
No open-market purchases or sales by Eledon Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $184.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Operating expenses | $83.3M | $70.6M | $43.0M | $88.4M | $36.9M |
| Research and development | $66.3M | $52.0M | $30.3M | $27.1M | $23.7M |
| Selling, general and administrative | $17.0M | $18.6M | $12.7M | $12.7M | $13.1M |
| Operating income | – | – | -$43.0M | -$88.4M | -$36.9M |
| Income tax | $35.0K | $431.0K | $0 | $0 | -$2.35M |
| Net income | -$45.6M | -$36.2M | -$116.5M | -$88.0M | -$34.5M |
| EPS, basic | $-0.52 | $-0.75 | $-4.73 | $-6.16 | – |
| EPS, diluted | $-0.52 | $-0.75 | $-4.73 | $-6.16 | – |
| Weighted shares, basic | 81.8M | 48.5M | 24.6M | 14.3M | – |
| Weighted shares, diluted | 81.8M | 48.5M | 24.6M | 14.3M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Cash and equivalents | $22.8M | $20.5M | $4.61M | $56.4M | $84.8M |
| Short-term investments | $110.5M | $119.6M | $46.5M | – | – |
| Total current assets | $135.7M | $143.7M | $56.1M | $59.5M | $88.3M |
| Goodwill | – | – | $0 | $0 | $48.6M |
| Total assets | $169.0M | $177.4M | $89.1M | $92.8M | $170.5M |
| Accounts payable | $3.63M | $5.83M | $967.0K | $2.20M | $1.81M |
| Total current liabilities | $18.3M | $11.6M | $3.90M | $6.47M | $4.40M |
| Total liabilities | $32.2M | $59.3M | $81.9M | $8.61M | $6.55M |
| Shareholders' equity | $81.1M | $62.4M | $7.21M | $84.2M | $164.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K/A | 10-K | 10-K |
| Reported | Mar 19, 2026 | Mar 20, 2025 | Mar 28, 2024 | Mar 30, 2023 | Mar 24, 2022 |
| Operating cash flow | -$62.3M | -$47.3M | -$39.5M | -$28.4M | -$28.9M |
| Stock-based compensation | $10.5M | $13.1M | $6.54M | $8.15M | $7.90M |
| Investing cash flow | $10.8M | -$70.3M | -$45.3M | – | – |
| Financing cash flow | $53.8M | $133.5M | $33.0M | – | -$449.0K |
| Net change in cash | $2.26M | $15.9M | -$51.8M | -$28.4M | -$29.4M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2026 | 84.5M | +40.9% | SEC |
| Aug 10, 2026 | 81.3M | +35.7% | SEC |
| May 7, 2026 | 77.2M | +28.9% | SEC |
| Mar 13, 2026 | 75.9M | +26.7% | SEC |
| Nov 7, 2025 | 59.9M | +0.3% | SEC |
| Aug 13, 2025 | 59.9M | +51.0% | SEC |
| Aug 12, 2025 | 59.9M | +51.0% | SEC |
| May 8, 2025 | 59.9M | +55.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.